Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeSt long-term follow-up treatment strategies trial in early rheumatoid arthritis
NL-OMON22114Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of indomethacin in rheumatoid arthritis (RA) (4 arms), sponsored by Merck & Co. Primary endpoints: Functional ability, Radiological damage and 1 more. Started Aug 2004; status: active, not recruiting.
02
Drugs
indomethacin
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON22114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22114.